Medication Guide

Abilify (Aripiprazole).
What It Does, Side Effects, and What to Expect.

Written & medically reviewed by Alice Tran, PMHNP-BC · June 2026 · 8 min read

Aripiprazole (Abilify) is an atypical antipsychotic that has become one of the most prescribed psychiatric medications in the United States -- not primarily for schizophrenia, but as an add-on for depression when an antidepressant alone is not providing enough relief. Understanding how it differs from older antipsychotics, what akathisia is, and what to expect helps make a more informed decision about whether it fits your situation.

This article is for informational purposes only and does not replace a conversation with your prescriber. Medication decisions should always be made with a licensed provider who knows your full history.

What Is Abilify?

Aripiprazole is classified as a third-generation or "atypical" antipsychotic, though its mechanism differs meaningfully from even other atypicals. Rather than simply blocking dopamine receptors (which older antipsychotics do), aripiprazole is a partial dopamine D2 agonist. It acts as a functional stabilizer: it blocks dopamine activity when dopamine is excessive, but activates dopamine pathways when activity is too low. This is why it tends to be more activating and less sedating than most other antipsychotics.

FDA-approved uses include:

Schizophrenia (adults and adolescents 13+)
Bipolar I disorder (manic and mixed episodes; maintenance)
Major depressive disorder -- as adjunctive (add-on) therapy when antidepressants alone are insufficient
Irritability associated with autistic disorder
Tourette's disorder

FDA Boxed Warning

Increased mortality in elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. In placebo-controlled studies in this population there was also a higher rate of cerebrovascular events, including stroke and transient ischemic attack, some of them fatal. Abilify is not approved for the treatment of patients with dementia-related psychosis.

Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Because Abilify is often used alongside an antidepressant, this warning applies here too. Anyone starting treatment should be watched closely for clinical worsening, agitation, or emerging suicidal thoughts, especially in the first months and whenever the dose changes. Abilify is not approved for depression in patients under 18.

Other FDA Warnings

Compulsive urges. The FDA has warned that aripiprazole can trigger intense, uncontrollable urges: gambling, shopping, binge eating, or compulsive sexual behavior. These urges usually stop when the dose is lowered or the medication is discontinued. Many patients never connect the behavior to the medication, so it is worth naming directly.

Neuroleptic malignant syndrome (NMS). A rare but life-threatening reaction to antipsychotic medication, with high fever, muscle rigidity, confusion, and unstable blood pressure or heart rate. It is a medical emergency. Seek emergency care immediately if these symptoms appear.

Abilify as an Antidepressant Add-On

The most common reason adults in a general psychiatric practice encounter Abilify is as an augmentation strategy for depression. When a patient has been on a reasonable dose of an antidepressant for a sufficient time and has had only partial response -- improvement in some areas but persistent residual symptoms -- adding a low dose of aripiprazole (typically 2 to 5 mg, much lower than doses used for schizophrenia) can provide meaningful additional benefit.

This is well supported by clinical trial evidence. The mechanism is thought to involve dopaminergic enhancement in the prefrontal cortex (which SSRIs do not directly affect) and modulation of serotonin receptor activity.

Side Effects

Akathisia -- the most important side effect to know about. Akathisia is an inner restlessness or compulsion to move that can be extremely distressing. It may present as an inability to sit still, pacing, or a sense of agitation that is hard to describe. It is dose-dependent and more common at higher doses. At the low doses used for depression augmentation it is less frequent but still possible. If you experience this, tell your prescriber -- dose reduction or switching to a different medication can resolve it.
Nausea -- common early on
Headache
Insomnia -- more common than sedation, given the activating profile
Dizziness
Weight gain -- moderate; less than olanzapine (Zyprexa) or quetiapine (Seroquel) but still present for many patients. Metabolic monitoring (weight, lipids, glucose) is recommended with long-term use.

About akathisia: Some patients stop Abilify because of this feeling without realizing what it is or that it can be managed. If you feel an unusual inner restlessness shortly after starting or increasing Abilify, name it to your prescriber. It is a recognized, treatable side effect -- not a sign that you are getting worse.

Long-Term Considerations

With long-term use of any antipsychotic, there is a risk of tardive dyskinesia (TD) -- involuntary repetitive movements, typically of the face, lips, or tongue. This risk is lower with aripiprazole than with older antipsychotics, but it is not zero. Periodic monitoring for early TD signs is recommended during ongoing treatment.

Metabolic effects (weight, blood sugar, cholesterol) should be monitored with laboratory tests during long-term treatment, particularly at higher doses.

Who Is Abilify a Good Fit For?

Patients with partially-treated depression who have not achieved full remission on an antidepressant alone
Bipolar disorder with depressive or mixed features
Patients who need an antipsychotic with lower sedation burden than quetiapine or olanzapine
Patients for whom weight gain with other augmentation agents (quetiapine, mirtazapine) is a significant concern